The utility of delta-9-tetrahydrocannibinol therapy in a multiple sclerosis patient with a neoplastic brain lesion

0Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Multiple sclerosis (MS) can sometimes cause uncommon pseudotumoural lesions that produce atypical symptoms, such as motor epileptic seizures which are often pharmacoresistant. In these cases, accurate diagnosis is essential for correct therapy, even if unconventional. We present the case of a brain tumour in a 40-year-old relapsing-remitting MS patient who presented with pharmacoresistant seizures which eventually responded to nabiximols. After various therapeutic approaches, delta-9-tetrahydrocannabinol therapy was introduced with good results. Spasticity improved, pain decreased and we observed a reduction in the number of daily seizures. It is possible that delta-9tetrahydrocannabinol can enhance the efficacy of anti-epilepsy therapy.

Cite

CITATION STYLE

APA

Fuiani, A. (2021). The utility of delta-9-tetrahydrocannibinol therapy in a multiple sclerosis patient with a neoplastic brain lesion. European Journal of Case Reports in Internal Medicine, 8(5). https://doi.org/10.12890/2021_002188

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free